All News

obese.waist_.jpg

GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis

Jack Cush, MD

Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA).

Read Article
RheumNow Podcast square

Telling You Where to Go (12.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients?

Read Article
AOSD.temp_.jpg

Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider

Jack Cush, MD

EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD).

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Optimizing Hydroxychloroquine Blood Levels in Lupus

Jack Cush, MD

A large observational cohort study suggests that monitoring hydroxychloroquine (HCQ) blood levels is effective in systemic lupus erythematosus (SLE) patients with a target therapeutic range (for HCQ level monitoring) of 750-1150 ng/ml.

Read Article
RheumNow Podcast square

APPs in the News (12.5.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salary concerns.

Read Article
PSA2L.jpg

Consensus Definitions on Difficult to Treat Psoriatic Arthritis

Jack Cush, MD

A substantial number of patients with psoriatic arthritis (PsA), have difficult, persistent and hard-to-treat disease. A GRAPPA task force has developed a consensus terminology for two distinct states: complex-to-manage PsA and treatment-refractory PsA.

Read Article
bechets.jpg

Organ Involvement with Behçet’s

Jack Cush, MD

A review of patient data from the International AutoInflammatory Disease Alliance (AIDA) Network registry identifying those with mucocutaneous Behçet’s disease (BD) may progres to major organ involvement (MOI)m especially at later stages.

Read Article
RheumNow Podcast square

Treating During Pregnancy (11.14.2025)

Jack Cush, MD

Dr. Jack Cush reviews the journal articles, news and guidelines from this past week on RheumNow.com

Read Article
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow Podcast (December 2025) https://t.co/icOauEOhLP https://t.co/eMt40WFiFD

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA teaching case: 57 yoF w/ RA Rx w/ HCQ, NSAID, TNFi (ETN -->ADA) develops a new rash - pruritic vesicles/papular on neck, mouth, ears, chest, hands w/ some becoming ulcerated plaques, ESR >100. WHAT TO DO? A) steroids; B) stop ADA; C) Benadryl or D) Read more? Pt had https://t.co/DQpeUOC5I3
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Dermatomyositis Reviewed Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options. https://t.co/0vDvqIcj6U https://t.co/ogPjPI5gJa

Links:

Dr. John Cush RheumNow ( View Tweet)
Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. https://t.co/XddFDe0xh8
Dr. John Cush RheumNow ( View Tweet)
Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. https://t.co/MNuQO6Dw5b
Dr. John Cush RheumNow ( View Tweet)
MEDISPO study of 38 mild-mod psoriasis pts, 16-wk Mediterranean diet vs low-fat diet. Mediterranean diet did much better w/ PASI change −3.4 vs 0, more pts achieving a PASI 75 reduction (47.4% vs none) https://t.co/ZJU58VanGr https://t.co/x6juAT672B

Links:

Dr. John Cush RheumNow ( View Tweet)
Israeli retrospective study of 9736 colchicine Rx FMF pts matched w/ 97 360 controls. On F/U Psoriatic arthritis developed in more FMF pts (43 vs 119) - HR 3.52 (CI: 2.48, 5.0). ^Risk w/ older age, smoking, SES https://t.co/blDIsmHWPC

Links:

Dr. John Cush RheumNow ( View Tweet)

DERM on RheumNow (November 2025) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side https://t.co/mX0Hv1RRF9
Dr. John Cush RheumNow ( View Tweet)
Betw 1990 to 2021 the global psoriasis burden had a slight increase w/ little difference betw men & women, roughly 57-61 100 000 (10% increase). Risk highest in N.America & W.Europe. PSO risk highest with higher incomes. https://t.co/raruHn5Txx https://t.co/bp1rWyWS7y

Links:

Dr. John Cush RheumNow ( View Tweet)
Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxn https://t.co/2qa7O2v6fm

Links:

Dr. John Cush RheumNow ( View Tweet)

IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the IL-23R, is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies. https://t.co/fYXULrMD16
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×